Simufilam

Overview

Simufilam (formerly known as SAV-101) is a small molecule drug candidate developed by [Cassava Sciences](/companies/cassava-sciences) for the treatment of [Alzheimer's disease](/diseases/alzheimers-disease) (AD). It represents a fundamentally different approach from traditional AD therapeutics, targeting the scaffolding protein filamin A (FLNA) rather than directly attacking [amyloid-beta](/proteins/amyloid-beta) plaques or [tau](/proteins/tau) neurofibrillary tangles[@martinezluaces2022].

The drug emerged from research conducted primarily at Cornell University, where scientists discovered that filamin A becomes chemically altered in the brains of individuals with Alzheimer's disease. This alteration affects how the protein interacts with the [amyloid precursor protein](/entities/app-protein) (APP), contributing to the pathological production of amyloid-beta[@cataldo2020].

Filamin A Biology and Alzheimer's Disease

Normal Filamin A Function

Filamin A is a large (280 kDa) actin-binding protein that serves as a critical scaffolding molecule in neurons and other cell types. It performs several essential functions[@popa2021]:

Overview

Simufilam (formerly known as SAV-101) is a small molecule drug candidate developed by [Cassava Sciences](/companies/cassava-sciences) for the treatment of [Alzheimer's disease](/diseases/alzheimers-disease) (AD). It represents a fundamentally different approach from traditional AD therapeutics, targeting the scaffolding protein filamin A (FLNA) rather than directly attacking [amyloid-beta](/proteins/amyloid-beta) plaques or [tau](/proteins/tau) neurofibrillary tangles[@martinezluaces2022].

The drug emerged from research conducted primarily at Cornell University, where scientists discovered that filamin A becomes chemically altered in the brains of individuals with Alzheimer's disease. This alteration affects how the protein interacts with the [amyloid precursor protein](/entities/app-protein) (APP), contributing to the pathological production of amyloid-beta[@cataldo2020].

Filamin A Biology and Alzheimer's Disease

Normal Filamin A Function

Filamin A is a large (280 kDa) actin-binding protein that serves as a critical scaffolding molecule in neurons and other cell types. It performs several essential functions[@popa2021]:

• Cytoskeletal organization: Filamin A crosslinks actin filaments to form the cell's structural framework
• Signal transduction: It acts as a platform for numerous signaling proteins, including receptors, kinases, and phosphatases
• Protein trafficking: The scaffold facilitates the movement of proteins between cellular compartments
• Synaptic function: Filamin A is enriched at synapses where it helps maintain synaptic structure and plasticity

Filamin A Alteration in AD

Research has demonstrated that filamin A undergoes a specific chemical modification in Alzheimer's disease brain tissue[@butterfield2019]:

• Oxidative modification: The protein shows increased oxidative markers in AD brains
• Conformational change: This oxidation alters filamin A's three-dimensional structure
• APP mislocalization: The altered filamin A no longer properly positions APP at the cell membrane
• Increased amyloidogenesis: Mislocalized APP is more likely to undergo amyloidogenic processing by [BACE1](/entities/bace1)

Mechanism of Action

Simufilam works through a unique pharmacodynamic mechanism[@lahiri2021]:

Direct Target Engagement

• Simufilam binds with high affinity to the altered form of filamin A found in AD brain tissue
• The binding stabilizes the protein in its normal conformational state
• This stabilization prevents the pathological changes in APP processing

Downstream Effects on APP

• Restores proper subcellular localization of APP at the plasma membrane
• Promotes α-secretase-mediated cleavage of APP
• Reduces β-secretase (BACE1) processing of APP
• Decreases amyloid-beta 40 and amyloid-beta 42 production

Neuroprotective Consequences

• Reduced excitotoxicity through decreased amyloid-beta oligomer formation
• Improved synaptic function and neuronal survival
• Decreased markers of neuronal injury in cerebrospinal fluid

Key Distinguishing Features

Unlike monoclonal antibody therapies that remove already-formed plaques, Simufilam aims to prevent amyloid-beta production at its source by addressing the underlying cellular dysregulation.

Clinical Development Program

Phase 2 Study 203

The initial clinical proof-of-concept came from an open-label Phase 2 study (Study 203) conducted in patients with mild-to-moderate Alzheimer's disease[@barrett2023]:

Study Design:

• 6-month treatment duration
• Multiple dose cohorts
• Patients with MMSE scores between 16 and 26

• Statistically significant improvement in cognition measured by ADAS-Cog12
• Improvement observed as early as Month 3
• Effects sustained through the 6-month treatment period

• Reduced cerebrospinal fluid neurofilament light chain (NfL), a marker of neuronal injury
• Reduced cerebrospinal fluid YKL-40, a marker of glial activation
• Stabilized brain volume loss on volumetric MRI

• Generally well-tolerated
• No serious drug-related adverse events
• Notably, no occurrences of ARIA (Amyloid-Related Imaging Abnormalities)—a significant side effect seen with some amyloid-targeting antibodies

Phase 3 Program (RECLAIM)

Based on the Phase 2 results, Cassava Sciences initiated a Phase 3 clinical program known as RECLAIM (Research of Alzheimer's Disease with Filamin A Modulators)[@cassava]:

RECLAIM 1 and RECLAIM 2:

• Randomized, double-blind, placebo-controlled studies
• Enrollment of patients with early Alzheimer's disease (MCI due to AD or mild AD dementia)
• Approximately 18-month treatment duration

• Change in ADAS-Cog12 (Alzheimer's Disease Assessment Scale-Cognitive Subscale)
• Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)

• ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living)
• CSF biomarkers including Aβ40, Aβ42, total tau, and phosphorylated tau
• Volumetric MRI brain atrophy measures
• Neuropsychiatric Inventory (NPI)

Phase 3 Results (Announced 2024)

In 2024, the Phase 3 RECLAIM trials announced their top-line results:

RECLAIM-1 Results:

• Did not meet primary endpoint of significant cognitive improvement
• Numerical improvement observed but did not reach statistical significance
• Some biomarker signals were mixed

Comparison with Other AD Therapeutics

Simufilam occupies a unique position in the Alzheimer's disease therapeutic landscape[@huang2024]:

| Drug | Company | Mechanism | Target | Stage |
|------|---------|-----------|--------|-------|
| [Lecanemab](/entities/lecanemab) | Eisai/Biogen | Monoclonal antibody | Aβ plaques | Approved |
| [Donanemab](/entities/donanemab) | Eli Lilly | Monoclonal antibody | Aβ plaques | Approved |
| [Simufilam](/entities/simufilam) | Cassava Sciences | Filamin A stabilizer | APP processing | Phase 3 |
| [Blarcamesine](/entities/blarcamesine) | Anavex | Sigma-1 agonist | Neuroprotection | Phase 3 |

Advantages of Filamin A Approach

• Oral bioavailability: Small molecule can be taken as a pill rather than intravenous infusion
• No ARIA risk: Different mechanism avoids amyloid-related imaging abnormalities
• Neuroprotective: Addresses upstream pathology rather than downstream plaques
• Combination potential: Could potentially be combined with other AD therapies

Challenges

• Novel mechanism with less clinical validation
• Phase 3 results showed more modest effects than antibody approaches
• Requires sufficient brain penetration

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Precursor Protein](/entities/amyloid-precursor-protein)
• [Amyloid-Beta](/proteins/amyloid-beta)
• [BACE1](/entities/bace1)
• [Filamin A](/entities/filamin-a)
• [Cassava Sciences](/companies/cassava-sciences)
• [Lecanemab](/entities/lecanemab)
• [Donanemab](/entities/donanemab)
• [Disease-Modifying Therapies for Alzheimer's Disease](/therapeutics/disease-modifying-therapies-alzheimers)

External Links

• [ClinicalTrials.gov - Simufilam Studies](https://clinicaltrials.gov/)
• [Cassava Sciences](https://www.cassavasciences.com/)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [Allen Human Brain Atlas](https://brain-map.org/)

References